Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free LENZ Stock Alerts

LENZ Therapeutics (LENZ) Competitors

LENZ Therapeutics logo
$4.68 +0.02 (+0.43%)
As of 08/21/2026 04:00 PM Eastern
Compare

LENZ vs. OVID, CTNM, AQST, EOLS, and RLMD

Should you buy LENZ Therapeutics stock or one of its competitors? LENZ Therapeutics's main competitors and comparable companies include Ovid Therapeutics (OVID), Contineum Therapeutics (CTNM), Aquestive Therapeutics (AQST), Evolus (EOLS), and Relmada Therapeutics (RLMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LENZ Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ovid Therapeutics currently has a consensus target price of $5.71, indicating a potential upside of 104.08%. LENZ Therapeutics has a consensus target price of $28.80, indicating a potential upside of 515.38%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Ovid Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Ovid Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ovid Therapeutics$7.25M75.43-$17.41M-$0.31N/A
LENZ Therapeutics$21.48M6.85-$82.13M-$4.09N/A

Ovid Therapeutics has a net margin of -240.11% compared to LENZ Therapeutics' net margin of -586.74%. Ovid Therapeutics' return on equity of -23.64% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ovid Therapeutics-240.11% -23.64% -20.52%
LENZ Therapeutics -586.74%-53.39%-49.14%

In the previous week, LENZ Therapeutics had 3 more articles in the media than Ovid Therapeutics. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Ovid Therapeutics. LENZ Therapeutics' average media sentiment score of 0.88 beat Ovid Therapeutics' score of 0.74 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ovid Therapeutics Positive
LENZ Therapeutics Positive

Ovid Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Summary

Ovid Therapeutics beats LENZ Therapeutics on 10 of the 17 factors compared between the two stocks.

How does LENZ Therapeutics compare to Contineum Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Contineum Therapeutics has higher revenue and earnings than LENZ Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$21.48M6.85-$82.13M-$4.09N/A
Contineum Therapeutics$50M12.93-$59.98M-$1.73N/A

Contineum Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Contineum Therapeutics' return on equity of -24.73% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-586.74% -53.39% -49.14%
Contineum Therapeutics N/A -24.73%-23.51%

In the previous week, Contineum Therapeutics had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 5 mentions for Contineum Therapeutics and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.88 beat Contineum Therapeutics' score of 0.51 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Contineum Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LENZ Therapeutics currently has a consensus price target of $28.80, indicating a potential upside of 515.38%. Contineum Therapeutics has a consensus price target of $20.25, indicating a potential upside of 17.80%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe LENZ Therapeutics is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Contineum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

54.3% of LENZ Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LENZ Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Summary

Contineum Therapeutics beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Aquestive Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

LENZ Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$21.48M6.85-$82.13M-$4.09N/A
Aquestive Therapeutics$44.54M13.13-$83.78M-$0.65N/A

LENZ Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

LENZ Therapeutics presently has a consensus target price of $28.80, indicating a potential upside of 515.38%. Aquestive Therapeutics has a consensus target price of $8.50, indicating a potential upside of 82.40%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Aquestive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Aquestive Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

Aquestive Therapeutics has a net margin of -144.63% compared to LENZ Therapeutics' net margin of -586.74%. Aquestive Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-586.74% -53.39% -49.14%
Aquestive Therapeutics -144.63%N/A -52.40%

In the previous week, Aquestive Therapeutics had 5 more articles in the media than LENZ Therapeutics. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.88 beat Aquestive Therapeutics' score of 0.74 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aquestive Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aquestive Therapeutics beats LENZ Therapeutics on 9 of the 17 factors compared between the two stocks.

How does LENZ Therapeutics compare to Evolus?

LENZ Therapeutics (NASDAQ:LENZ) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Evolus has a net margin of -10.85% compared to LENZ Therapeutics' net margin of -586.74%. Evolus' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-586.74% -53.39% -49.14%
Evolus -10.85%N/A -13.00%

In the previous week, LENZ Therapeutics had 1 more articles in the media than Evolus. MarketBeat recorded 3 mentions for LENZ Therapeutics and 2 mentions for Evolus. Evolus' average media sentiment score of 1.04 beat LENZ Therapeutics' score of 0.88 indicating that Evolus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evolus
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LENZ Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Evolus has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evolus has higher revenue and earnings than LENZ Therapeutics. Evolus is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$21.48M6.85-$82.13M-$4.09N/A
Evolus$297.18M1.86-$51.64M-$0.52N/A

LENZ Therapeutics presently has a consensus price target of $28.80, indicating a potential upside of 515.38%. Evolus has a consensus price target of $14.50, indicating a potential upside of 72.82%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Evolus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Evolus
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Evolus beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Relmada Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 159.18%. LENZ Therapeutics has a consensus price target of $28.80, indicating a potential upside of 515.38%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, LENZ Therapeutics had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for LENZ Therapeutics and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.92 beat LENZ Therapeutics' score of 0.88 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Relmada Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Relmada Therapeutics' return on equity of -47.52% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -47.52% -43.97%
LENZ Therapeutics -586.74%-53.39%-49.14%

Relmada Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.90N/A
LENZ Therapeutics$21.48M6.85-$82.13M-$4.09N/A

Summary

Relmada Therapeutics beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LENZ vs. The Competition

Export
MetricLENZ TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$146.42M$12.45B$7.26B$12.77B
Dividend YieldN/A2.64%2.54%11.08%
P/E Ratio-1.14789.80273.1824.24
Price / Sales6.85960.98689.62129.21
Price / CashN/A92.1276.8953.23
Price / Book0.6711.8913.456.38
Net Income-$82.13M$2.81B$3.47B$348.73M
7 Day Performance-1.06%1.77%2.08%0.08%
1 Month Performance-12.36%3.52%6.10%2.91%
1 Year Performance-88.30%6.57%24.99%17.19%

LENZ Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LENZ
LENZ Therapeutics
3.257 of 5 stars		$4.68
+0.4%		$28.80
+515.4%		-88.3%$146.42M$21.48MN/A110
OVID
Ovid Therapeutics
2.2989 of 5 stars		$2.84
-1.7%		$5.71
+101.2%		+192.6%$554.65M$7.25MN/A60
CTNM
Contineum Therapeutics
1.1456 of 5 stars		$14.48
-0.3%		$20.25
+39.8%		+71.2%$544.74M$50MN/A31
AQST
Aquestive Therapeutics
2.1237 of 5 stars		$4.32
+0.7%		$8.50
+96.8%		+19.2%$542.21M$54.09MN/A160
EOLS
Evolus
2.9629 of 5 stars		$8.16
+5.0%		$14.50
+77.7%		+12.9%$538.97M$297.18MN/A170

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
A Worldwide Gold Lockdown Is Now Underway
Gold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...
Stansberry Research | Sponsoredtc pixel
What is Trump’s decade-long obsession?
No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...
Brownstone Research | Sponsoredtc pixel